Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2179-2183

  Riedel, Frank ^a   Götte, Karl ^a   Goessler, Ulrich ^a   Sadick, Hannen ^a   Hörmann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Antisense; Chemotherapy; Head and neck cancer; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444248801     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lingen MW: Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med 10: 153-164, 1999.
2. Mashberg A: Head and neck cancer. N Engl J Med 328: 1783-1784, 1993.
3. Dimery IW and Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111, 1993.
4. Hong WK, Bromer RH, Amato DA, Shapshay S, Vincent M, Vaughan C, Willett B, Katz A, Welch J, Fofonoff S et al: Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 56: 1242-1245, 1985.
5. Haddad RI, Wirth L and Posner MR: Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther 3: 331-338, 2003.
6. Calatayud S, Warner TD and Mitchell JA: Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. Br J Cancer 86: 1316-1321, 2002.
7. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995.
8. Kuehn R, Rojas W, Riedel F, Bergler W and Hörmann K: Tumour angiogenesis in head and neck squamous cell carcinoma. Br J Cancer 77: Suppl. 1, 27, 1995.
9. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
10. Folkman J and Klagsbrun M: Angiogenetic factors. Science 235: 442-447, 1987.
11. Dvorak HF, Brown LF, Detmar M and Dvorak HM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
12. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
13. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL and Bicknell R: Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Nat Cancer Inst 87: 213-219, 1995.
14. Eisma RJ, Spiro JD and Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997.
15. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A and Wennerberg J: Prognostic value of vascular endothelial growth factor in head and neck squamous cell carcinomas. Br J Cancer 83: 775-781, 2000.
16. Salven P, Heikkilä P, Anttonen A, Kajanti M and Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Modern Pathol 10: 1128-1133, 1997.
17. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W and Hörmann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Oto-Rhino-Laryngol 257: 332-336, 2000.
18. Riedel F, Götte K, Schwalb J, Schäfer C and Hörmann K: Expresson of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Oto-Laryngol 120: 105-111, 2000.
19. Riedel F, Götte K; Bergler W and Hörmann K: Inverse correlation of angiogenic and apoptotic markers in squamous cell carcinoma of the head and neck. Oncology Rep 8: 471-476, 2001.
20. Brekken RA and Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumours. Anticancer Res 21: 4221-4229, 2001.
21. Manley PW, Martiny-Baron G, Schlaeppi JM and Wood JM: Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11: 1715-1736, 2002.
22. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F and Albini A: Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 27: 229-238, 2003.
23. Miller KD, Sweeney CJ and Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001.
24. Lennernas B, Albertsson P, Lennernas H and Norrby K: Chemotherapy and antiangiogenesis-drug-specific, dose-related effects. Acta Oncol 42: 294-303, 2003.
25. Kerbel RS: A cancer therapy resistant to resistance. Nature 390: 335-336, 1997.
26. Teicher BA: Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9: 475-506, 1995.
27. Shannon AM, Bouchier-Hayes DJ, Condron CM and Toomey D: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29: 297-307, 2003.
28. Kakeji Y, Maehara Y, Ikebe M and Teicher BA: Dynamics of tumour oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 37: 1115-1123, 1997.
29. Bassukas ID, Vester G and Maurer-Schultze B: Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamide. Virchows Arch B Cell Pathol Incl Mol Pathol 59: 251-256, 1990.
30. Zhang XS, Zhu XF, Gao JS, Qian CN, Kuang ZJ, Liu ZC and Zeng YX: Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol Sin 22: 731-735, 2001.
31. Mirabelli CK, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 6: 647-661, 1991.
32. Kim R, Tanabe K, Emi M, Uchida Y and Toge T: Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review). Int J Oncol 24: 5-17, 2004.
33. Riedel F, Gotte K, Li M, Hormann K and Grandis JR: Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int J Oncol 23: 577-583, 2003.
34. Smyth AP, Rook SL, Detmar M and Robinson GS: Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 108: 523-526, 1997.
35. Zheng SX, Zhou LJ, Zhu XZ and Jin YZ: Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor in human glioma cells. Acta Pharmacol Sin 21: 211-214, 2000.
36. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R and Smith LE: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93: 4851-4856, 1996.
37. Field AK and Goodchild J: Antisense oligonucleotides: Rational drug design for genetic pharmacology. Exp Opin Invest Drugs 4: 799-821, 1995.
38. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D and Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17: 3586-3595, 1999.
39. Kerbel RS, Viloria-Petit A, Klement G and Rak J: 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36: 1248-1257, 2000.